Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 1/20 | 0.36 |
| ▸ | OPRD1 known ✓ | P41143 | 1/20 | 0.36 |
| ▸ | OPRK1 known ✓ | P41145 | 1/20 | 0.36 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | CTSB | P07858 | 3/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | GPR35 | Q9HC97 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | CTSH | P09668 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 5/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5590081 | 0.81 | SMN1; SMN2 (0.46) | HPGDSMN1; SMN2CTSBTP53TSHR | |
| SCHEMBL1349673 | 0.80 | FBP1 (0.37) | HPGDSMN1; SMN2TP53TSHRCYP3A4 | |
| SCHEMBL13322828 | 0.77 | GPR35 (0.56) | SMN1; SMN2CTSBTSHRGPR35HSD17B10 | |
| SCHEMBL2526898 | 0.76 | CA1 (0.41) | HPGDSMN1; SMN2ALDH1A1MAPTLMNA | |
| SCHEMBL14562946 | 0.76 | PDK1 (0.35) | HPGDTSHRCYP3A4ALDH1A1L3MBTL1 | |
| SCHEMBL2526896 | 0.76 | CA1 (0.41) | HPGDSMN1; SMN2ALDH1A1MAPTLMNA | |
| Phosphoric Acid SCHEMBL28852824 | 0.75 | GRIN2D (0.39) | GPR35MAPK1HSD17B10ALOX15L3MBTL1 | |
| SCHEMBL8091152 | 0.74 | PDK1 (0.42) | SMN1; SMN2TSHRCYP3A4ALDH1A1MAPK1 | |
| Phosphoric Acid SCHEMBL28031480 | 0.74 | ESR1 (0.37) | POLBHSP90AA1 | |
| SCHEMBL2033188 | 0.74 | PGK1 (0.38) | SMN1; SMN2TSHRCYP3A4ALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260062460-A1 | METHODS FOR TREATING ACUTE CORONARY SYNDROME USING APOA-1 FUSION PROTEINS | THERIPION, INC. (US) | 2026-03-05 | — | — | US | disclosed |
| US-12509501-B2 | Polynucleotides encoding APOA-1 fusion polypeptides | THERIPION, INC. (US) | 2025-12-30 | — | — | US | disclosed |
| US-12497604-B2 | RNase-PON1 fusion polypeptides and related compositions and methods | THERIPION, INC. (US) | 2025-12-16 | — | — | US | disclosed |
| US-20250206806-A1 | POLYNUCLEOTIDES ENCODING APOA-1 FUSION POLYPEPTIDES | THERIPION, INC. (US) | 2025-06-26 | — | — | US | disclosed |
| US-12331102-B2 | APOA-1 fusion polypeptides and related compositions | THERIPION, INC. (US) | 2025-06-17 | — | — | US | disclosed |
| US-20250154484-A1 | RNASE-PON1 FUSION POLYPEPTIDES AND RELATED COMPOSITIONS AND METHODS | THERIPION, INC. (US) | 2025-05-15 | — | — | US | disclosed |
| US-20250145977-A1 | METHODS FOR TREATING RHEUMATOID ARTHRITIS USING CTLA4-PON1 FUSION PROTEINS | THERIPION, INC. (US) | 2025-05-08 | — | — | US | disclosed |
| US-12258596-B2 | Polynucleotides encoding paraoxonase fusion polypeptides | THERIPION, INC. (US) | 2025-03-25 | — | — | US | disclosed |
| US-20250059525-A1 | POLYNUCLEOTIDES ENCODING PARAOXONASE FUSION POLYPEPTIDES | THERIPION, INC. (US) | 2025-02-20 | — | — | US | disclosed |
| US-12180521-B2 | Paraoxonase fusion polypeptides and related compositions and methods | THERIPION, INC. (US) | 2024-12-31 | — | — | US | disclosed |
| WO-2022178078-A1 | PARAOXONASE FUSION POLYPEPTIDES AND RELATED COMPOSITIONS AND METHODS | THERIPION, INC. (US) | 2022-08-25 | — | — | WO | disclosed |
| CN-111195531-B | Hybrid material of multi-pyridine zinc complex modified MIL-101, preparation method and application of hybrid material in catalyzing degradation of organic phosphorus | 安徽师范大学 | 2022-08-02 | — | — | CN | disclosed |
| US-20220089687-A1 | POLYNUCLEOTIDES ENCODING APOA1-PON1 FUSION POLYPEPTIDES | THERIPION INC (US) | 2022-03-24 | — | — | US | disclosed |
| CN-111195531-A | Hybrid material of multi-pyridine zinc complex modified MIL-101, preparation method and application of hybrid material in catalyzing degradation of organic phosphorus | 安徽师范大学 | 2020-05-26 | — | — | CN | disclosed |
| EP-3328881-B1 | APOA-1 FUSION POLYPEPTIDES AND RELATED COMPOSITIONS AND METHODS | THERIPION INC (US) | 2019-08-28 | — | — | EP | disclosed |
| WO-2018136163-A2 | TANDEM APOA-1 FUSION POLYPEPTIDES | THERIPION, INC. (US) | 2018-07-26 | — | — | WO | disclosed |
| US-20180201664-A1 | APOA-1 FUSION POLYPEPTIDES AND RELATED COMPOSITIONS AND METHODS | THERIPION, INC. | 2018-07-19 | — | — | US | disclosed |
| EP-3328881-A1 | APOA-1 FUSION POLYPEPTIDES AND RELATED COMPOSITIONS AND METHODS | Theripion, Inc. (US) | 2018-06-06 | — | — | EP | disclosed |
| WO-2017044424-A1 | APOA-1 FUSION POLYPEPTIDES AND RELATED COMPOSITIONS AND METHODS | THERIPION, INC. (US) | 2017-03-16 | — | — | WO | disclosed |
| US-20020151068-A1 | Compositions and methods for the diagnosis and treatment of organophosphate toxicity | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2002-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260062460-A1 | METHODS FOR TREATING ACUTE CORONARY SYNDROME USING APOA-1 FUSION PROTEINS | PON1, APOB, APOL1 | HRH1 1473/4885OPRD1 2764/4885OPRK1 3528/4885 |
| US-12509501-B2 | Polynucleotides encoding APOA-1 fusion polypeptides | APOB, PON1, APOL1 | HRH1 2862/4885OPRD1 3023/4885OPRK1 3778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.